Therefore, we propose that hDM should be far less immunogenic than the currently used bacterial enzymes. Conclusion In this study, we have demonstrated the feasibility of ADEPT in which both the enzyme Torin 2 clinical trial and the targeting moiety are of human origin. Our study has shown that hDM, a version of human PNP with only two amino acid substitutions, can be fused to a targeting component comprised of a human-derived scFv without loss of activity. Moreover, we have shown that the drug generated by the enzymatic activity of hDM causes tumor cell death
regardless of their expression of tumor associated antigen or growth rate. We anticipate that effective tumor cell targeting of hDM will result in localized tumor cytotoxicity in vivo. Our findings should provide important insights into approaches for the development of superior all human ADEPT. Acknowledgements The work was supported by National Institutes of Health Grant selleck compound RO1 GM074051 and by the National Institutes of Health Clinical & Fundamental Immunology Training Grant, NIH
T32AI07126. FLOW cytometry was performed in the UCLA Jonsson Comprehensive Cancer see more Center (JCCC) and Center for AIDS research Flow Cytometry Core Facility that is supported by National Institutes of Health award CA-16042 and AI-28697 and by the JCCC, the UCLA AIDS Institute, the David Geffen School of Medicine at UCLA and the UCLA Chancellor’s Office. References 1. Bagshawe KD, Sharma SK, Springer CJ, Rogers GT: Antibody directed enzyme prodrug therapy (ADEPT). A review Fenbendazole of some theoretical, experimental and clinical
aspects. Ann Oncol 1994, 5: 879–891.PubMed 2. Bagshawe KD, Sharma SK, Springer CJ, Antoniw P, Boden IA, Rogers GT, Burke PJ, Melton RG, Sherwood RF: Antibody directed enzyme prodrug therapy (ADEPT): clinical report. Dis Markers 1991, 9: 233–8.PubMed 3. Xu G, McLeod HL: Strategies for Enzyme/Prodrug Cancer Therapy. Clin Cancer Res 2001, 7: 3314–3324.PubMed 4. Springer CJ, Niculescu-Duvaz I: Prodrug-activating systems in suicide gene therapy. J Clin Invest 2000, 105: 1161–7.CrossRefPubMed 5. Afshar S, Asai T, Morrison SL: Humanized ADEPT Comprised of an Engineered Human Purine Nucleoside Phosphorylase and a Tumor Targeting Peptide for Treatment of Cancer. Mol Cancer Ther 2009, 8 (1) : 1–9.CrossRef 6. Stoeckler JD, Poirot AF, Smith RM, Parks RE, Ealick SE, Takabayashi K, Erion MD: Purine Nucleoside Phosphorylase. 3. Reversal of Purine Base Specificity by Site-Directed Mutagenesis. Biochemistry 1997, 36: 1174–1175.CrossRef 7. Schier R, McCall A, Adams GP, Marshall KW, Merritt H, Yim M, Crawford RS, Weiner LM, Marks C, Marks JD: Isolation of Picomolar Affinity Anti-c-erbB-2 Single-chain Fv by Molecular Evolution of thE Complementarity Determining Regions in the Center of the Antibody Binding Site. J Mol Biol 1996, 263: 551–567.CrossRefPubMed 8.